Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, issue.3, pp.161-172, 2018. ,
Heterogeneity in malignant pleural mesothelioma, Int J Mol Sci, vol.19, issue.6, 2018. ,
Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, issue.5, pp.1323-1334, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478599
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, issue.4, pp.407-416, 2016. ,
Integrative molecular characterization of malignant pleural mesothelioma, Cancer Discov, vol.8, issue.12, pp.1548-1565, 2018. ,
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group, Arch Pathol Lab Med, vol.137, issue.5, pp.647-667, 2013. ,
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications, Nat Commun, vol.10, issue.1, p.1333, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02090279
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, issue.3, pp.277-293, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma, J Thorac Oncol, vol.12, issue.5, pp.850-859, 2017. ,
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (ifct-1501 maps2): A multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, issue.2, pp.239-253, 2019. ,